Perma-Fix Q3 2026: Treatment Backlog Surges on Hanford DFLAW Volumes, Services Turns Profitable

What happened

Perma-Fix reported Q3 2026 results with sequential revenue growth of 39% and a 25% increase in treatment backlog from Q2 2026, bringing the backlog to $19.6 million, up approximately 65% from year-end 2025. The key development is that Perma-Fix Northwest has begun receiving both liquid effluent and dry waste from the Direct-Feed Low-Activity Waste (DFLAW) facility at Hanford, validating the company's positioning for DOE tank waste secondary streams. The Services segment reversed its prior weakness with revenue up 46% year over year, gross margin improving to 12.2% from 6.7%, and the segment posting positive operating income. This marks a significant improvement from the Q3 2025 master report, which highlighted Services as a drag and Treatment revenue at $13.1 million with a $15.4 million backlog. However, the press release does not provide details on cash position, free cash flow, PFAS commercialization progress, or share count, leaving key risk factors from the previous analysis unresolved.

Implication

The DFLAW acceptance is a concrete milestone that de-risks the Hanford opportunity and supports higher Treatment utilization, directly addressing a key uncertainity in the prior bear case. The Services segment's return to growth and positive operating income reduces a major drag on consolidated profitability and could improve overall margins. The $19.6 million backlog provides near-term revenue visibility and implies that quarterly Treatment revenue likely exceeded the $13 million threshold set in the master report for a potential upgrade to POTENTIAL BUY. However, investors should await the Q3 2026 10-Q to confirm the cash balance, free cash flow trends, and any dilution, as these were critical risks flagged previously. If the financials confirm sustained high Treatment revenue with stable margins and moderating cash burn, the stock could warrant a more constructive rating, but PFAS commercialization still needs to be demonstrated before a full bullish turn.

Thesis delta

The previous WAIT thesis was conditioned on an upgrade if Treatment revenue exceeded $13 million quarterly with stable margins through 2026; the Q3 2026 results strongly suggest that condition has been met, shifting the balance of evidence in favor of a potential upgrade. The Services segment's positive operating income further reduces a key bear concern and supports the bull case. However, the lack of detailed financials in the press release (cash, FCF, PFAS) means we cannot yet confirm the upgrade, and we will reassess upon the 10-Q filing.